Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal of Oregon.
Press releases published on September 16, 2025
KFSHRC reduziert Wartezeit für Betten in der Notaufnahme um 75 %
RIAD, Saudi-Arabien, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Das King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riad hat die durchschnittliche Wartezeit in der Notaufnahme von über 13 Stunden im Jahr 2023 auf nur noch 3,2 Stunden bis Mitte 2025 …
KFSHRC réduit de 75 % le temps d’attente aux urgences pour obtenir une hospitalisation
RIYAD, Arabie saoudite, 16 sept. 2025 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSHRC) à Riyad a réduit le temps d’attente médian aux urgences, qui est passé de plus de 13 heures en 2023 à seulement 3,2 heures au milieu …
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in multi-functional fusion protein molecule that exhibits …
SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial
ALISO VIEJO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced the appointment of Anand Sundaram as the company’s Vice President, Head of Commercial. Mr. Sundaram brings over a decade of …
Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo
LAGUNA HILLS, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid’s native token, HYPE, today …
Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™
SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Medicines360, a women’s health innovation organization with a mission to be a catalyst for change, today announced that it has acquired global licensing rights to PeriPeach, an investigational medical …
Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD
New U.S. patent provides IP coverage for the formulation to 2042 Further expands Starton’s intellectual property portfolio surrounding its lead product candidate, STAR-LLD, Method of Use Patent #11,197,852 which provides IP coverage to 2040 PARAMUS, N.J., …
Parexel Announces Appointment of Rob Goodwin as Chief Operating Officer
RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry, today announced the appointment of Rob …
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five years of …
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025 Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“ …
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
MADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it continues to expand its patent …
Marine Biologics Partners with Molecular Quantum Solutions to Accelerate Next-Generation Biomaterials Development
BERKELEY, Calif. and COPENHAGEN, Denmark, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biomaterials company Marine Biologics today announced an exclusive strategic partnership with Molecular Quantum Solutions (MQS) in which Marine Biologics will be the sole …
Highridge Medical Enters Exclusive Distribution Agreement for the PathKeeper Surgical Navigation System
WESTMINSTER, Colo., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Highridge Medical, one of the world’s largest privately held spine companies with an innovative and clinically supported portfolio, announced today it has entered into an exclusive distribution …
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract …
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management - GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company …
Izotropic Publishes New FAQ Page for Investors, Analysts, and Healthcare Decision-Makers
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging …
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
First data on treatment of NPC1 with Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients1 showed stabilization or improvement in CGI-S score Data presented at the15th …
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will …
Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced the Company is in the process of addressing comments received by the U.S. Food and Drug Administration (FDA) in connection with the …